This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bethoux, F. Articles by Kinkel, R P. Search for Related Content PubMed PubMed Citation Articles by Bethoux, F. Articles by Kinkel, R P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METHYLPREDNISOLONE Medline Plus Health Information Steroids Social Bookmarking                         What's this?

Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life

The Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Deborah M Miller

The Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

R Philip Kinkel

The Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

To observe the pattern of recovery after treatment with intravenous Methylprednisolone (i.v. MP) for a relapse of multiple sclerosis (MS), and to determine the best time to plan further interventions such as rehabilitation, we assessed consecutive outpatients (n=24) treated with i.v. MP for a relapse over a period of 12 weeks. Outcomes measures used were the Expanded Disability Status Scale (EDSS), the Incapacity Status Scale (ISS), the MOS Short Form-36 (SF-36), the Mental Health Inventory (MHI), and the MS-Related Symptom Checklist (MSSCL). There was statistically significant early improvement of EDSS and ISS scores, which was sustained until week 12, and significant improvement of MHI and MSSCL scores between 4 and 12 weeks. Although trends for improvement of scores reflecting the same pattern of recovery were observed with the SF-36 physical and mental composites, these changes did not reach statistical significance. Our results suggest that improvement of impairments and disability after treatment with i.v. MP for a relapse of MS occurs early, while improvement of subjective health status is delayed. Even after maximum improvement is reached, patients are left with multiple symptoms and functional limitations, and may benefit from additional rehabilitative interventions.

Key Words: multiple sclerosis • methylprednisolone • disability • quality of life • SF-36 • rehabilitation

Multiple Sclerosis, Vol. 7, No. 2, 137-142 (2001)
DOI: 10.1177/135245850100700210


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A Giordano, E Pucci, P Naldi, L Mendozzi, C Milanese, F Tronci, M Leone, N Mascoli, L La Mantia, G Giuliani, et al. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study J. Neurol. Neurosurg. Psychiatry, September 1, 2009; 80(9): 1023 - 1028. [Abstract] [Full Text] [PDF]

				D. Kos, M. Duportail, M. D'hooghe, G. Nagels, and E. Kerckhofs Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial Multiple Sclerosis, September 1, 2007; 13(8): 996 - 1003. [Abstract] [PDF]

				J Craig, C A Young, M Ennis, G Baker, and M Boggild A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment J. Neurol. Neurosurg. Psychiatry, September 1, 2003; 74(9): 1225 - 1230. [Abstract] [Full Text] [PDF]

				M W Nortvedt and T Riise The use of quality of life measures in multiple sclerosis research Multiple Sclerosis, February 1, 2003; 9(1): 63 - 72. [Abstract] [PDF]